Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 29, 2006 Brian Lawler	Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide.
The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
Chemistry World October 17, 2012 Maria Burke	GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency.
The Motley Fool December 27, 2006 Brian Lawler	Telik Falls Short Shares of another biopharma fall after disappointing clinical trial results.
The Motley Fool January 25, 2007 Brian Lawler	Renovis Tries to Right Itself Renovis takes some steps to try and recover after its lead drug fails in clinical testing. Investors, take note.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool April 2, 2008 Brian Lawler	A Slate of Data for Exelixis Exelixis will present analyses of study data at the American Society of Clinical Oncology in May for all of its lead cancer-fighting compounds. Investors, take note.
The Motley Fool May 22, 2007 Brian Lawler	Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool November 21, 2007 Brian Orelli	Phase 2 Data to Sink Your Teeth Into Novo Nordisk releases encouraging phase 2 clinical data about its weight-loss/diabetes drug, liraglutide. Investors, take note.
Chemistry World February 7, 2013 Maria Burke	GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public.
The Motley Fool December 26, 2006 Brian Lawler	InterMune's Secret Drug Surprise Shares of InterMune have risen after positive trial results for one of its top drug candidates. Investors, take note.
The Motley Fool October 11, 2006 Brian Lawler	Waiting on Northfield The development-stage drug company waits for clinical trial results. Until the fate of its lead product is known, most of Northfield's financial results will be of peripheral importance to investors at best.
The Motley Fool July 10, 2006 Brian Lawler	Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced.
The Motley Fool October 24, 2006 Brian Lawler	Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note.
The Motley Fool September 5, 2006 Brian Lawler	Adolor: Positive Results, Negative Reaction The market seems confused by good results from Adolor's latest clinical trial. Investors willing to take a gamble on Adolor at this price may be in for huge rewards if the company and Glaxo can convince the FDA of Entereg's viability.
The Motley Fool July 25, 2007 Brian Orelli	Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors.
The Motley Fool September 27, 2007 Brian Orelli	Incyte's Double Dose of Trial News With two drugs providing good results in preliminary trials, and another five medications in early-stage clinicals, Incyte is a shining example of a developmental-stage drugmaker. Investors, take note.
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
Chemistry World September 17, 2013 Phillip Broadwith	GSK criticized for trial data secrecy An Italian research institute has withdrawn from a public -- private partnership after quarrelling with GlaxoSmithKline about access to data from an antibiotic clinical trial being run by the institute.
The Motley Fool May 23, 2008 Brian Orelli	Progenics' Mixed Trial Data Progenics Pharmaceuticals and marketing partner Wyeth release both positive and negative clinical trial data.
The Motley Fool May 9, 2007 Mike Havrilla	Scintillating Synta Patient investors should peek at this pharma's promising pipeline.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool January 3, 2007 Brian Lawler	Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note.
The Motley Fool February 28, 2007 Brian Lawler	Threshold Over the Edge Another day, another development-stage drugmaker implodes. Investors, Threshold announced negative clinical trial results for its lead drug.
The Motley Fool April 23, 2007 Brian Lawler	Neurochem Sets Low Expectations The specialty drug developer announces an update on plans to release results from a clinical study. Investors, take note.
The Motley Fool June 5, 2007 Brian Lawler	Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note.
The Motley Fool December 8, 2004 Alyce Lomax	Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days.
Pharmaceutical Executive September 1, 2008 Melanie North	Publish or Perish FDAAA means that companies need to register clinical trials; and not only for publication planning.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool June 12, 2009 Brian Orelli	Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
Bio-IT World July 2005 Kevin Davies	Trial Registries on Trial A group of influential editors from some of the world's boutique medical journals begin enforcing a new policy that would bar drug companies from publishing clinical trial data unless those trials are registered in a suitable public database.
Bio-IT World August 2005 Ellen H. Julian	Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources.
The Motley Fool November 20, 2006 Brian Lawler	One-and-a-Half Setbacks for Exelixis Drug development is a long process usually involving many setbacks and failures, even for the most successful drug makers. Investors in this biotech shouldn't worry too much about this one.
The Motley Fool December 12, 2008 Brian Orelli	Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA.
The Motley Fool April 26, 2007 Tom Taulli	Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
The Motley Fool December 19, 2008 Brian Orelli	Open-Label Bites Drug Duo Pfizer and Celldex have to make the best of a bad situation.
Pharmaceutical Executive October 1, 2005 Lisa Grimes	Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction.
The Motley Fool August 16, 2007 Brian Orelli	Novacea's (Statistically) Significant Change The pharmaceutical increases the number of subjects in its latest clinical trial.
The Motley Fool July 20, 2007 Brian Orelli	Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit.
Chemistry World October 15, 2013 Dinsa Sachan	Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed.
The Motley Fool September 26, 2006 Brian Lawler	Four-Bagger Biotech in One Day Acorda's shares zoomed up, but potential investors should be cautious.
The Motley Fool September 25, 2007 Brian Orelli	No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes.
The Motley Fool January 29, 2008 Brian Lawler	Acorda Rides the Wave Acorda Therapeutics announces positive clinical trial data on its lead multiple sclerosis drug.
The Motley Fool May 29, 2008 Brian Lawler	Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing.
The Motley Fool August 27, 2007 Brian Orelli	Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up.
The Motley Fool March 21, 2007 Brian Lawler	InterMune Slims Down InterMune announces changes after its lead compound fails in a study. Investors, take note.
The Motley Fool November 11, 2010 Brian Orelli	ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial.